Evista

Evista is formulated for treatment of osteoporosis, it also reduces risk of breast cancer in postmenopausal women with osteoporosis.

Product dosage: 60mg
Package (num)	Per pill	Price	Buy
30	1.95 $	58.50 $ (0%)	🛒 Add to cart
60	1.52 $	117.00 $ 91.26 $ (22%)	🛒 Add to cart
90	1.38 $	175.50 $ 124.02 $ (29%)	🛒 Add to cart
120	1.32 $	234.00 $ 157.95 $ (33%)	🛒 Add to cart
180	1.24 $	351.00 $ 223.47 $ (36%)	🛒 Add to cart
270	1.20 $	526.50 $ 322.92 $ (39%)	🛒 Add to cart
360	1.17 $ Best per pill	702.00 $ 422.37 $ (40%)	🛒 Add to cart
Synonyms Bonmax Optruma Osral Raloxifeno Raloxifenum

Evista (raloxifene hydrochloride) is a selective estrogen receptor modulator (SERM) specifically designed for postmenopausal women to combat bone loss and reduce fracture risk. It offers a targeted approach to osteoporosis management by mimicking estrogen’s beneficial effects on bone density without stimulating uterine or breast tissue. Clinically proven to increase bone mineral density, Evista represents a cornerstone in long-term skeletal health strategy for appropriate patient populations. Its dual benefit profile makes it a preferred option for women seeking both osteoporosis treatment and breast cancer risk reduction.

Features

• Contains raloxifene hydrochloride as the active ingredient
• Available in 60 mg tablet formulation
• Selective estrogen receptor modulator (SERM) class medication
• Designed for once-daily oral administration
• FDA-approved for osteoporosis treatment and prevention in postmenopausal women
• Also indicated for reduction in risk of invasive breast cancer in high-risk postmenopausal women
• Non-hormonal mechanism of action
• Manufactured under strict quality control standards

Benefits

• Significantly increases bone mineral density in the spine and hip
• Reduces risk of vertebral fractures by approximately 30-50%
• Lowers incidence of invasive breast cancer in high-risk populations
• Provides estrogen-like benefits to bone without endometrial stimulation
• Offers convenient once-daily dosing regimen
• Maintains bone protective effects with long-term use
• Does not cause menstrual bleeding or breast tenderness
• May improve lipid profiles by lowering LDL cholesterol

Common use

Evista is primarily prescribed for the treatment and prevention of osteoporosis in postmenopausal women. It is particularly valuable for women who cannot or prefer not to take traditional hormone replacement therapy. Physicians often recommend Evista for patients with low bone density who have additional risk factors for breast cancer, as it provides dual protection. The medication is typically prescribed as part of a comprehensive bone health program that includes adequate calcium and vitamin D intake, weight-bearing exercise, and fall prevention strategies. Treatment duration usually continues for several years, with periodic reassessment of bone density and risk factors.

Dosage and direction

The recommended dosage is one 60 mg tablet taken orally once daily, with or without food. Patients should swallow the tablet whole with water and not crush or chew it. Timing of administration should be consistent each day, though specific time of day is not critical. For optimal absorption, avoid taking calcium supplements, antacids, or other mineral supplements within 2 hours of Evista administration. Treatment should be continued as long as therapeutic benefit persists, typically for several years under medical supervision. Regular bone density monitoring is recommended every 1-2 years to assess treatment response.

Precautions

Patients should undergo thorough medical evaluation before initiating therapy, including assessment of venous thromboembolism risk factors. Regular gynecological examinations are recommended due to the potential for rare but serious uterine effects. Liver function should be monitored periodically as raloxifene is extensively metabolized hepatically. Patients should maintain adequate calcium and vitamin D intake through diet or supplements. Those with impaired renal function require careful monitoring. Women should be advised about the importance of weight-bearing exercise and fall prevention measures. Smoking cessation and alcohol moderation should be encouraged as part of comprehensive bone health management.

Contraindications

Evista is contraindicated in women with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. It must not be used in patients with known hypersensitivity to raloxifene hydrochloride or any tablet components. The medication is contraindicated in premenopausal women and during pregnancy or lactation. Women with hepatic impairment or significant renal dysfunction should avoid use. Concurrent use with systemic estrogen therapy is not recommended. Patients with unexplained uterine bleeding should not use Evista until appropriate diagnostic evaluation is completed.

Possible side effects

Common side effects include hot flashes (most frequently reported), leg cramps, peripheral edema, and flu-like symptoms. Some women experience arthralgia, myalgia, or sweating. Gastrointestinal disturbances such as nausea, vomiting, and abdominal pain may occur. Serious but rare adverse effects include venous thromboembolism, which requires immediate medical attention if symptoms develop. Rare cases of retinal vein thrombosis and superficial thrombophlebitis have been reported. Some patients may experience weight changes or headache. Most side effects are mild to moderate and often diminish with continued therapy.

Drug interaction

Evista may interact with warfarin, requiring more frequent monitoring of prothrombin time. Cholestyramine and other anion exchange resins significantly reduce raloxifene absorption and should not be taken concurrently. Highly protein-bound drugs may potentially displace raloxifene from binding sites. Concurrent use with systemic estrogens is not recommended. Ampicillin and other antibiotics that reduce enteric bacteria may decrease raloxifene efficacy. The medication may affect lipid-lowering therapy effectiveness. Clinicians should review all medications, including over-the-counter products and supplements, before prescribing Evista.

Missed dose

If a dose is missed, the patient should take it as soon as remembered on the same day. If the missed dose is not remembered until the next day, the patient should skip the missed dose and resume the regular schedule. Never double the dose to make up for a missed tablet. Consistent daily administration is important for maintaining therapeutic effect, but occasional missed doses are unlikely to significantly affect overall efficacy. Patients should maintain their regular dosing schedule and contact their healthcare provider if multiple doses are missed or if uncertainty exists about proper dosing.

Overdose

Limited information exists regarding Evista overdose, as no fatal cases have been reported. In clinical trials, single doses up to 600 mg and multiple doses up to 300 mg daily for 8 weeks were tolerated. Potential symptoms may include leg cramps, dizziness, and rash. There is no specific antidote for raloxifene overdose. Treatment should be supportive and symptomatic. Gastric lavage may be considered if ingestion occurred recently. Activated charcoal may be administered if appropriate. Patients should receive medical observation and supportive care based on clinical manifestations. Hemodialysis is unlikely to be beneficial due to high protein binding.

Storage

Store at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep the medication in its original container with the lid tightly closed. Protect from light, moisture, and excessive heat. Do not store in bathroom cabinets where humidity levels fluctuate. Keep out of reach of children and pets. Do not use if the tablets appear discolored, damaged, or beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations for pharmaceutical waste.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Individual patient needs may vary, and healthcare professionals should make treatment decisions based on clinical judgment and patient-specific factors. The prescribing physician should be consulted for complete information regarding indications, contraindications, warnings, precautions, and adverse effects. Patients should not alter or discontinue medication without medical supervision. Full prescribing information is available from the manufacturer and should be reviewed before initiating therapy.

Reviews

Clinical studies demonstrate Evista’s efficacy in increasing bone mineral density by 2-3% at the spine and 2-2.5% at the hip over two years. The MORE trial showed a 30-50% reduction in vertebral fractures among postmenopausal women with osteoporosis. Breast cancer risk reduction studies indicate approximately 76% decrease in invasive breast cancer incidence in high-risk populations. Patient satisfaction surveys report good tolerability, though vasomotor symptoms remain a concern for some users. Long-term follow-up data support maintained efficacy with 5-8 years of continuous therapy. Real-world evidence confirms the clinical trial results in diverse patient populations.